Clinical Research Directory

Inclusion Criteria: * Recipient of 7-8/8 HLA-matched allogeneic hematopoietic stem cell transplantation or recipient of haploidentical allogenic hematopoietic stem cell transplantation. * Age 2 and up. * Must have steroid-refractory chronic GVHD that is still active despite at least 4 weeks of treatment with low-dose subcutaneous (SC) IL-2. * Stable dose of glucocorticoids for 2 weeks prior to enrollment * no addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment. * Must have adequate organ and marrow function. * Ability to understand and willingness to sign a written informed consent form. * Donor who is willing and cleared to donate starting material for manufacture of EVE-Treg. Exclusion Criteria: * Recipient of umbilical cord blood stem cell graft. * Ongoing prednisone requirement greater than 1 mg/kg/day (or equivalent). * Karnofsky/Lansky performance score less than 40%. * Concurrent use of methotrexate, azathioprine, or a calcineurin-inhibitor plus sirolimus. * Other investigational agents within 4 weeks prior to enrollment. * Participants with post-transplant exposure to donor lymphocyte infusion, or T-cell or IL-2 targeted medications within 100 days prior to enrollment. * Participants with new immunosupprssive medication, extra-corporeal photopheresis or rituximab therapy initiated int he 4 weeks prior to enrollment. * Participants with active malignant relapse or recrudescence of their prior hematologic disorder. * Uncontrolled intercurrent illness unrelated to cGVHD. * Participants with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant patients are excluded.